| Literature DB >> 27321995 |
Harinath Doodhi1, Andrea E Prota2, Ruddi Rodríguez-García1, Hui Xiao3, Daniel W Custar4, Katja Bargsten2, Eugene A Katrukha1, Manuel Hilbert2, Shasha Hua1, Kai Jiang1, Ilya Grigoriev1, Chia-Ping H Yang3, David Cox5, Susan Band Horwitz3, Lukas C Kapitein6, Anna Akhmanova7, Michel O Steinmetz8.
Abstract
Microtubules are dynamic polymers built of tubulin dimers that attach in a head-to-tail fashion to form protofilaments, which further associate laterally to form a tube. Asynchronous elongation of individual protofilaments can potentially lead to an altered microtubule-end structure that promotes sudden depolymerization, termed catastrophe [1-4]. However, how the dynamics of individual protofilaments relates to overall growth persistence has remained unclear. Here, we used the microtubule targeting anti-cancer drug Eribulin [5-7] to explore the consequences of stalled protofilament elongation on microtubule growth. Using X-ray crystallography, we first revealed that Eribulin binds to a site on β-tubulin that is required for protofilament plus-end elongation. Based on the structural information, we engineered a fluorescent Eribulin molecule. We demonstrate that single Eribulin molecules specifically interact with microtubule plus ends and are sufficient to either trigger a catastrophe or induce slow and erratic microtubule growth in the presence of EB3. Interestingly, we found that Eribulin increases the frequency of EB3 comet "splitting," transient events where a slow and erratically progressing comet is followed by a faster comet. This observation possibly reflects the "healing" of a microtubule lattice. Because EB3 comet splitting was also observed in control microtubules in the absence of any drugs, we propose that Eribulin amplifies a natural pathway toward catastrophe by promoting the arrest of protofilament elongation.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27321995 DOI: 10.1016/j.cub.2016.04.053
Source DB: PubMed Journal: Curr Biol ISSN: 0960-9822 Impact factor: 10.834